Segantii Capital Management’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Segantii Capital Management’s Portfolio LSBPW Stock Details LSBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$320K	–	249
2023 Q1	$320K	Buy	+200,000	New	+$30.3K	0.01%	252

Other funds holding LSBPW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return

BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Segantii Capital Management's LSBPW Position: Q2 2023 in Review

Segantii Capital Management sold out of LakeShore Biopharma Warrants (LSBPW) in Q2 2023, closing a stake of 200,000 shares — an estimated $320K sold.

Segantii Capital Management first reported a position in LSBPW in Q1 2023 and held it in 1 quarter. The position peaked at $320K in Q1 2023. 31 funds tracked by Wall St. Rank hold LSBPW as of Q2 2023.

Segantii Capital Management reported no remaining LakeShore Biopharma Warrants position as of Q2 2023 after selling out during the quarter.
Segantii Capital Management sold 200,000 LakeShore Biopharma Warrants shares in Q2 2023, an estimated $320K.
Segantii Capital Management first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 1 quarter.
Segantii Capital Management's LakeShore Biopharma Warrants position peaked at $320K in Q1 2023.
31 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q2 2023.

Based on Segantii Capital Management's 13F filing for Q2 2023, filed 2 Aug 2023.